GeoVax Labs, Inc. Enters into Agreement with Vaxeal Holding SA
January 03, 2018
Share
GeoVax Labs Inc. entered into an agreement with Vaxeal Holding SA for GeoVax Labs’ cancer immunotherapy program. GeoVax’s immuno-oncology program is based on its Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. Under the agreement, GeoVax Labs will collaborate with Vaxeal on the expansion of GeoVax’s cancer immunotherapy program. The collaboration will include the design, construction, characterization and animal testing of vaccine candidates using GeoVax’s MVA-VLP vaccine platform. Vaccine antigens will include Vaxeal’s proprietary designed sequences. The agreement enables GeoVax Labs and Vaxeal to expand application of MVA-VLP vaccine technology with multiple collaborations in immuno-oncology.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
GEOVAX LABS, INC. 
